IBAB:EBR
Ion Beam Applications SA
16,38 €
arrow_upward
+1,11%(+0,18) 1D
16 հոկ, 17:35:27 GMT+2 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for IBAB...
Open
16,20 €
High
16,56 €
Low
16,12 €
Mkt. cap
498,81 մլն
Avg. vol.
14,82 հզր
Volume
17,31 հզր
Dividend
1,07%
Quarterly dividend
0,04 €
Ex-dividend date
15 հնս, 2026 թ.
P/E ratio
20,58
52-wk high
17,76 €
52-wk low
9,90 €
EPS
0,80 €
Shares outstanding
30,28 մլն
No. of employees
2 հզր
Open
16,20 €
High
16,56 €
Low
16,12 €
Mkt. cap
498,81 մլն
Avg. vol.
14,82 հզր
Volume
17,31 հզր
Dividend
1,07%
Quarterly dividend
0,04 €
Ex-dividend date
15 հնս, 2026 թ.
P/E ratio
20,58
52-wk high
17,76 €
52-wk low
9,90 €
EPS
0,80 €
Shares outstanding
30,28 մլն
No. of employees
2 հզր
News stories
From web sources and news partners
Yahoo Finance
·
18 ժամ առաջ
IBA and Framatome join forces to industrialize Astatine-211 production for cancer therapies
Profile
IBA is a medical technology company based in Louvain-la-Neuve. The company was founded in 1986 by Yves Jongen within the Cyclotron Research Center of the University of Louvain and became a university spin-off. It employs about 1500 people in 40 locations. The company developed cyclotrons and integrated proton therapy centers is active in the field of proton therapy, dosimetry, radiopharmacy solutions and industrial sterilisation.
IBA installed its first proton therapy equipment for Boston's Massachusetts General Hospital in 2001, and for University of Pennsylvania's Proton Center in 2009.
It supplied equipment and services to Proton Partners International which was developing three proton beam therapy centers in the United Kingdom.
In 2017, IBA invested €16 million in the construction of a new logistics and production center in Louvain-la-Neuve. Wikipedia
About Ion Beam Applications SA